Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer.

ABSTRACT:

Background

Epidermal growth factor receptor (EGFR) is frequently overexpressed in metastatic triple-negative breast cancer (mTNBC). One strategy for overcoming resistance to EGFR inhibition is concomitant inhibition of downstream signaling. The antidiabetic drug metformin inhibits both MAPK and PI3K/mTOR pathway signaling. We evaluated the combination of erlotinib and metformin in a phase 1 study of patients with mTNBC.

Patients and methods

Patients with mTNBC who had received at least one prior line of therapy for metastatic disease were eligible. Erlotinib dose was fixed at 150 mg daily. Metformin dose escalation was planned according to a 3 + 3 design. Dose-limiting toxicities (DLT) were assessed during the first 5 weeks of therapy. The primary objective was to determine

SUBMITTER: Fenn K 

PROVIDER: S-EPMC7304226 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature